‘Verrica Pharmaceuticals incorporated Continues to Make Strides in Dermatology Therapeutics\n\nWEST CHESTER, Pa., November 10, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals incorporated (Nasdaq:VRCA) is a leading dermatology therapeutics company that focuses on developing medications for skin diseases requiring medical interventions. The company’s latest developments and future plans will be presented by President & Chief Executive Officer, Ted White, at the upcoming Jefferies Global Healthcare Conference in London on November 15, 2023.\n\nThe conference, taking place from November 14-16, 2023, will feature Verrica’s President & Chief Executive Officer, Ted White, who will discuss the company’s latest developments and future plans. A replay of the webcast will also be available on the website for 90 days following the event.\n\nVerrica Pharmaceuticals incorporated is a dermatology therapeutics company that focuses on developing medications for skin diseases requiring medical interventions. Their lead product, YCANTH™ (cantharidin), was approved by the FDA in July 2023 for the treatment of molluscum contagiosum, a highly contagious viral skin infection. The company is also developing VP-102 for the treatment of common warts and external genital warts, and VP-103 for plantar warts. Additionally, Verrica has a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatologic oncology conditions.\n\nVerrica’s President & Chief Executive Officer, Ted White, will be presenting at the Jefferies Global Healthcare Conference in London on November 15, 2023. The presentation will provide updates on the company’s latest developments and future plans. Interested individuals can access a live webcast of the event on the Verrica website at www.verrica.com. A replay of the webcast will also be available on the website for 90 days following the event.\n\nVerrica Pharmaceuticals incorporated Reports Third Quarter 2023 Financial Results\n\nIn a Verrica Pharmaceuticals incorporated continues to make strides in the field of dermatology therapeutics. With the first FDA-approved product for the treatment of molluscum, the company is seeing widespread interest and availability of YCANTH™.’